Patient Enrollment for Phase 3 UGN-103 Trial in LG-IM-NMIBC Complete

Fact checked by" Ariana Pelosci
News
Article

The phase 3 UTOPIA trial has enrolled a total of 99 patients with low-grade intermediate-risk NMIBC to receive UGN-103.

The phase 3 UTOPIA trial has enrolled a total of 99 patients with low-grade intermediate-risk NMIBC to receive UGN-103.

The phase 3 UTOPIA trial has enrolled a total of 99 patients with low-grade intermediate-risk NMIBC to receive UGN-103.

Patient enrollment has been finalized for the single-arm phase 3 UTOPIA trial (NCT06331299) evaluating intravesical solution for UGN-103, a mitomycin-based formulation, in patients with recurrent low-grade intermediate risk non–muscle invasive bladder cancer (NMIBC), according to a press release from the developer, UroGen Pharma.1

The trial has enrolled a total of 99 patients across various global centers.

In September 2024, the developer received a notice of allowance from the US Patent and Trademark Office that covered the utilization of UGN-103 for low-grade intermediate-risk NMIBC; patient protection is expected through December 2041. Additionally, in January 2024, the developer entered into a licensing and supply agreement with medac to develop UGN-103 for this patient population.

“Completing enrollment in the UTOPIA trial marks a significant milestone in our efforts to advance UGN-103 as a next-generation treatment option for patients with recurrent [low-grade intermediate-risk] NMIBC,” stated Michael Louie, MD, EVP, of Medical Affairs and Clinical Development at UroGen, in the press release.1 “UGN-103 represents a pivotal advancement in our pipeline, aiming to deliver the same non-surgical benefits to patients as mitomycin [Zusduri], while also enhancing operational efficiency and convenience for providers.”

The trial enrolled patients with low-grade NMIBC, defined as grade Ta, histologically confirmed by cold cup biopsy at screening or within 8 weeks before screening; they also had intermediate-risk, defined as having the presence of multiple tumors, solitary tumor size larger than 3 cm, or early or frequent recurrence.2 Additional enrollment criteria include a history of at least 1 prior episode of NMIBC, negative voiding cytology for high-grade disease within 8 weeks before screening, adequate organ and bone marrow function, a life expectancy at least the duration of the trial, and contraceptive use consistent with local regulations.

Those who received Bacillus Calmette-Guérin therapy for urothelial carcinoma within the past year, with a history of high-grade bladder cancer in the past 2 years, with known sensitivity to any component of study treatment, and with a clinically significant urethral structure that precludes passage of a urethral catheter were excluded from participating. Additional grounds for exclusion included a history of neurogenic bladder, active urinary retention, and any other condition that prohibits normal voiding; past or current muscle invasive bladder cancer or metastatic urothelial carcinoma; current tumor stage of T1; concurrent upper tract urothelial carcinoma; evidence of active urinary tract infection that cannot be resolved; any other active malignancy requiring anticancer therapy; and previous participation in a study administering UGN-102.

All patients received 75 mg of UGN-103 via intravesical instillation once per week for 6 weeks. UGN-103 uses RTGel® technology, a reverse-thermal hydrogel enabling sustained drug release and prolonged bladder exposure. The developer noted that UGN-103 is designed to offer a shorter manufacturing process and simplified reconstitution procedure when compared with mitomycin (Zusduri) for intravesical solution.

The trial’s primary end point was the complete response (CR) rate at 3 months. Secondary end points include duration of response; durable CR rate; incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs of special interest, and abnormal clinical laboratory test results; mitomycin plasma concentrations; and mitomycin maximum plasma concentration.

Patients who do not have a CR at the 3-month visit will undergo investigator-assigned standard of care and have a separate end-of-study visit performed. Those who do undergo a CR enter a follow-up phase of up to 12 months to assess the durability of response.

References

  1. UroGen announces completion of enrollment in the phase 3 UTOPIA clinical trial of UGN-103 for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. News release. UroGen Pharma. July 7, 2025. Accessed July 7, 2025. https://tinyurl.com/3cx2m95t
  2. A phase 3 study of UGN-103 for treatment of patients with low-grade intermediate-risk non-muscle invasive Bladder cancer (UTOPIA). ClinicalTrials.gov. Updated April 9, 2025. Accessed July 7, 2025. https://tinyurl.com/m9htzwx8
Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content